Posted by Michael Wonder on 03 Aug 2021
Hansa Biopharma announces reimbursement in the Netherlands of Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
2 August 2021 - Idefiris (imlifidase) for enabling kidney transplantation in highly sensitised patients is now reimbursable and available for use in the Netherlands.
Hansa Biopharma today announces that its first-in-class treatment Idefirix (imlifidase) is, as of August 1, reimbursable and available for use in the Netherlands.
